Generate:Biomedicines, a pioneering force in the application of generative artificial intelligence (AI) in drug development, announced significant advancements in its clinical pipeline and expanded collaboration with Amgen at the 42nd Annual J.P. Morgan Healthcare Conference.
Clinical Breakthroughs and Strategic Collaborations
Mike Nally, CEO of Generate:Biomedicines and CEO-Partner at Flagship Pioneering, will present the company's strides in generative biology, emphasizing the dosing of the first patient in the GB-0895 study, advancements in the GB-0669 phase 1 study, and an expansion of their collaboration agreement with Amgen.
"In 2023, we made substantial advances in computational and experimental capabilities, shaping the future of generative biology," said Nally.
Key Highlights from Generate:Biomedicines' Pipeline:
- GB-0895: An anti-TSLP monoclonal antibody for mild-to-moderate asthma, with the first patient dosed in the UK. The study, also conducted in Germany, focuses on safety and tolerability, aiming to select optimal doses/regimens for further development.
- GB-0669: Targeting a critical region of the SARS-CoV-2 spike protein, this monoclonal antibody has shown safety in initial cohorts and potent in vitro neutralization of major variants.
The Generate Platform demonstrates exceptional multiparameter co-optimization capabilities, producing assets with best-in-class profiles. This includes potent anti-IL-13 monoclonal antibodies for type-2 inflammation-mediated diseases and anti-hemagglutinin antibodies targeting influenza. The platform's success in generating de novo binders and deploying structure in the learning loop marks a significant innovation in therapeutic discovery.
Pharma
